Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Agilent Technologies's Revenue for the
three
months ended in Apr. 2026 was MXN32,142 Mil. Agilent Technologies's average Accounts Receivable for the
three
months ended in Apr. 2026 was MXN26,314 Mil.
Hence, Agilent Technologies's Receivables Turnover for the
three
months ended in Apr. 2026 was 1.22.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Agilent Technologies Receivables Turnover Related Terms
Agilent Technologies Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:A vs NTRA, WAT, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (MEX:A) has a Receivables Turnover of 1.22 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Agilent Technologies and its competitors. According to the industry distribution chart, Agilent Technologies ranks #99 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 49%.
Is Agilent Technologies' Receivables Turnover too high?
Agilent Technologies' current Receivables Turnover is 1.22. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Agilent Technologies' value of 1.22 is 77.3% below this industry median. Based on the distribution chart, Agilent Technologies ranks #99 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Receivables Turnover compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #99 out of 202 companies for Receivables Turnover. This puts Agilent Technologies in the upper half of its industry. The industry median Receivables Turnover is 5.38. Agilent Technologies' value of 1.22 is 77.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agilent Technologies's current Receivables Turnover of 1.22 is 77.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Agilent Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current Receivables Turnover is 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (MEX:A) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,535.46, compared to a current price of MXN2,350.00 — trading 7.3% below its estimated fair value. The current Receivables Turnover is 1.22 and 77.3% below the Medical Diagnostics & Research industry median of 5.38. Agilent Technologies' overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Agilent Technologies (MEX:A), the current Receivables Turnover is 1.22 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (MEX:A) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of MXN2,350.00 is trading 7.3% below its estimated GF Value™ of MXN2,535.46.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for MEX:A:
Receivables Turnover: 1.22
GF Value™: MXN2,535.46 vs. price of MXN2,350.00 (7.3% below fair value)
Industry Position: 77.3% below the Medical Diagnostics & Research median (#99 of 202)
No single metric tells the full story. See the MEX:A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
89GF Score
Get the complete analysis for MEX:A
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:A has been successfully added to your 
